DJIA 18,288.63 155.93 0.86%
NASDAQ 5,008.10 44.57 0.90%
S&P 500 2,117.39 12.89 0.61%
market minute promo

Emergent BioSolutions (NYSE: EBS)

30.10 0.13 (0.43%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EBS $30.10 0.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $29.92
Previous Close $29.97
Daily Range $29.70 - $30.42
52-Week Range $19.31 - $30.74
Market Cap $1.1B
P/E Ratio 51.67
Dividend (Yield) $0.00 (0.0%)
Volume 217,763
Average Daily Volume 203,940
Current FY EPS $1.27




Drug Makers

Emergent BioSolutions (EBS) Description

Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website:

News & Commentary Rss Feed

3 Fast-Growing Biotech Stocks To Buy in December

You don't want to miss out on these tiny biotechs expected to see earnings grow sharply in 2015.

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

Health Care Sector Update for 02/13/2015: GSK, EBS, CPHD

Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog

Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog

Worried About a Market Crash? These 3 Stocks Soared During the Great Recession

Catamaran Corp., Cantel Medical, and Emergent BioSolutions all gained ground during the Great Recession, suggesting that they might be good stocks to watch if markets head south.

Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog

Emergent BioSolutions Inc Busts Through Guidance. Sort of.

Emergent BioSolutions' upfront payment from its deal with MorphoSys caused a large increase in revenue in the third quarter.

Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q3 2014 Results - Earnings Call Transcript

Emergent BioSolutions (EBS) Q3 2014 Results - Earnings Call Webcast

See More EBS News...

EBS's Top Competitors

EBS $30.10 (0.43%)
Current stock: EBS
AMGN $159.63 (1.21%)
Current stock: AMGN
GILD $103.83 (0.29%)
Current stock: GILD
BIIB $415.79 (1.51%)
Current stock: BIIB